Jane Street’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$671K Sell
27,000
-112,200
-81% -$2.9M ﹤0.01% 7357
2025
Q4
$3.54M Buy
139,200
+59,600
+75% +$1.33M ﹤0.01% 3774
2025
Q3
$1.28M Buy
79,600
+22,000
+38% +$356K ﹤0.01% 5793
2025
Q2
$922K Sell
57,600
-106,200
-65% -$1.61M ﹤0.01% 5769
2025
Q1
$2.8M Buy
163,800
+95,500
+140% +$2M ﹤0.01% 3819
2024
Q4
$1.69M Sell
68,300
-200
-0.3% -$5.67K ﹤0.01% 4421
2024
Q3
$1.95M Buy
68,500
+8,900
+15% +$262K ﹤0.01% 4525
2024
Q2
$1.57M Sell
59,600
-22,500
-27% -$640K ﹤0.01% 4921
2024
Q1
$2.65M Buy
82,100
+20,400
+33% +$744K ﹤0.01% 3615
2023
Q4
$2.6M Sell
61,700
-182,700
-75% -$6.72M ﹤0.01% 3864
2023
Q3
$9.38M Buy
+244,400
New +$5.52M ﹤0.01% 1851
2023
Q1
Sell
-13,100
Closed -$233K 9441
2022
Q4
$233K Buy
+13,100
New +$165K ﹤0.01% 7433
2022
Q1
Sell
-83,300
Closed -$710K 10644
2021
Q4
$710K Sell
83,300
-460,400
-85% -$3.8M ﹤0.01% 6602
2021
Q3
$4.72M Sell
543,700
-138,000
-20% -$1.24M ﹤0.01% 2831
2021
Q2
$7.21M Buy
+681,700
New +$9.52M ﹤0.01% 2111

Other funds holding IMVT

Jane Street's IMVT Position: Q1 2026 in Review

Jane Street opened a new position in Immunovant (IMVT) in Q1 2026: 84,312 shares worth $2.09M. The stake represents ﹤0.01% of the portfolio and ranks #4991 among its holdings. This is a return to the name: Jane Street previously reported a position in IMVT as recently as Q3 2025.

Jane Street first reported a position in IMVT in Q1 2020 and has held it in 21 quarters since. The position peaked at $25.9M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Jane Street held 84,312 shares of Immunovant worth $2.09M as of Q1 2026.
  • Immunovant was a new Jane Street position in Q1 2026.
  • Immunovant made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4991 holding.
  • Jane Street first reported a position in Immunovant in Q1 2020 and has held it in 21 quarters since.
  • Jane Street's Immunovant position peaked at $25.9M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.